Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) A pharmaceutical oral controlled release composition comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide.

Claim 2. (Original) The pharmaceutical composition according to claim 1 being a disintegrating tablet with modified release granules comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide.

Claim 3. (Original) The pharmaceutical composition according to claim 2 wherein the 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide is present in the granules in an amount of from 60 to 90 % by weight of the modified release granules.

Claim 4. (Currently amended) A pharmaceutical composition according to claim 2 ~~or 3~~ comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide having a median particle size between 150 and 300 µm.

Claim 5. (Currently amended) A pharmaceutical composition according to claim 2 ~~any one of claims 2 to 4~~ wherein the modified release granules comprise as retarding agent at least one polymer selected from polymethacrylates, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and methylcellulose.

Claim 6. (Original) A pharmaceutical composition according to claim 5 comprising polymethacrylates and ethylcellulose wherein the polymethacrylates are present in the granules in an amount of 5 to 25 % by weight of the modified release granules.

Claim 7. (Currently amended) A pharmaceutical composition according to claim 5 ~~or 6~~ comprising polymethacrylates and ethylcellulose wherein the ethylcellulose is present in the granules in an amount of from 2 to 10 % by weight of the modified release granules.

Claim 8. (Currently amended) A pharmaceutical composition according to claim 1 ~~any one of claims 1 to 7~~ comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide in an amount of from 50 to 80 % by weight of the total composition.

Claim 9. (Currently amended) A pharmaceutical composition according to claim 1 ~~any one of claims 1 to 8~~ comprising microcristalline cellulose.

Claim 10. (Currently amended) A pharmaceutical composition according to claim 1 ~~any one of claims 1 to 9~~ comprising at least one natural starch as disintegrant.

Claim 11. (Original) The pharmaceutical composition according to claim 10 comprising maize starch as disintegrant.

Claim 12. (Original) A pharmaceutical oral controlled release composition comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, wherein in use 70 to 90 % of said 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide are released within 6 hours indicated in standard in-vitro dissolution tests at 37° in phosphate buffer having a pH of about 6.8 for a 500 mg dosage form.

Claim 13. (Original) The pharmaceutical oral controlled release composition comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide according to claim 12, wherein in use 80 to 90 % of said 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide are released within 6 hours indicated in standard in vitro dissolution tests at 37° in phosphate buffer having a pH of about 6.8 for a 500 mg dosage form.

Claim 14. (Currently amended) A pharmaceutical oral controlled release composition according to claim 1 ~~any one of claims 1 to 13~~ having no food effect.

Claim 15. (Original) A disintegrating tablet having modified release granules comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and at least one polymer as retarding agent adapted to be administered once a day.

Claim 16. (Original) The disintegrating tablet according to claim 15 wherein the at least one polymer is selected from polymethacrylates, ethylcellulose, hydroxyethylcellulose, hydroxypropyl-cellulose and methylcellulose.

Claim 17. (Currently amended) A disintegrating tablet according to claim 15 ~~or 16~~ having no food effect.

Claim 18. (Original) A pharmaceutical oral controlled release composition comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide displaying a plateau profile between about 4 and 25 hours after administration.

Claim 19. (Currently amended) Use of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and excipients as defined in claim 1 ~~any one of claims 1 to 18~~ for the preparation of a medicament for the treatment of patients with affective disorders.

Claim 20. (Currently amended) A method of orally administering 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide for the treatment of affective disorders, said method comprising orally administering to a patient in need of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide therapy once a day a pharmaceutical composition according to claim 1. ~~any one of claims 1 to 18.~~